Histone Acetyltransferase Inhibitor Anacardic Acid Causes Changes in Global Gene Expression during In Vitro Plasmodium falciparum Development

Long Cui,1‡ Jun Miao,1‡ Tetsuya Furuya,2§ Qi Fan,1 Xinyi Li,1 Pradipsinh K. Rathod,3 Xin-zhuan Su,2 and Liwang Cui1*

Department of Entomology, The Pennsylvania State University, 501 ASI Building, University Park, Pennsylvania 16802; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892; and Bagley Hall 192H, Department of Chemistry, University of Washington, Seattle, Washington 98195

Received 17 February 2008/Accepted 6 May 2008

To better understand the role of histone lysine acetylation in transcription in Plasmodium falciparum, we sought to attenuate histone acetyltransferase (HAT) activity using anacardic acid (AA). We showed that AA reversibly and noncompetitively inhibited the HAT activity of recombinant PIGCN5. To a lesser extent, AA inhibited the PIGCN5 activity in parasite nuclear extracts but did not affect histone deacetylase activity. AA blocked the growth of both chloroquine-sensitive and -resistant strains, with a 50% inhibitory concentration of ~30 μM. Treatment of the parasites with 20 μM of AA for 12 h had no obvious effect on parasite growth or gross morphology but induced hypoacetylation of histone H3 at K9 and K14, but not H4 at K5, K8, K12, and K16, suggesting inhibition of the PIGCN5 HAT. Microarray analysis showed that this AA treatment resulted in twofold or greater change in the expression of 271 (~5%) parasite genes in late trophozoites, among which 207 genes were downregulated. Cluster analysis of gene expression indicated that AA mostly downregulated active genes, and this gene pool significantly overlapped with that enriched for H3K9 acetylation. We further demonstrated by chromatin immunoprecipitation and real-time PCR that AA treatment reduced acetylation near the putative promoters of a set of downregulated genes. This study suggests that the parasiticidal effect of AA is at least partially associated with its inhibition of PIGCN5 HAT, resulting in the disturbance of the transcription program in the parasites.

Chromatin is the physiological template for cellular processes such as DNA replication, repair, and transcription in eukaryotes. Histones, the major protein components of chromatin, not only play essential roles in packaging nuclear DNA but also serve as key regulators of genomic function (26). Histone tails are subjected to a plethora of posttranslational modifications including acetylation, methylation, phosphorylation, ubiquitylation, and sumoylation, which altogether constitute the “histone code” (7, 35, 50). These modifications affect the physical architecture of chromatin (10), generate binding platforms recognized by other proteins (19), and are important elements of epigenetic gene regulation.

The most extensively studied histone modification event is lysine acetylation, regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). Based on a number of conserved structure motifs, HATs are divided into GNAT (GCN5-related N-acetyltransferase), MYST (MOZ, YBF2/SAS3, and Tip60), and p300/CREB-binding protein (CBP) (48). These HAT families use different catalytic mechanisms: whereas p300 catalyzes a double-displacement reaction (53), the GNAT family members GCN5 and PCAF (p300/CBP associated factor) are involved in the ordered binding and release of substrates and products (52). Despite extensive pharmaceutical efforts, only a few HAT inhibitors are known to date (54). Lys-coenzyme A (Lys-CoA) and H3-CoA-20 are potent, selective inhibitors of the HATs p300/CBP and PCAF, respectively (38), but their impermeability to cells limits their uses in vivo. Along this line, a series of Lys-CoA derivatives with enhanced cell permeability have been synthesized, and some of them possess potent inhibitor activities against p300 both in vitro and in vivo (57). Toward the development of synthetic HAT inhibitors, Biel et al. designed γ-butyrolactone derivatives as GCN5 inhibitors (8). High-throughput screening also led to the identification of isothiazolones as inhibitors of PCAF and p300, which have antiproliferative activity against tumor cell lines (49). A Saccharomyces cerevisiae-based assay system has been used to screen natural and synthetic compounds and determine their specificity for GCN5 (41, 46). Recently, chemicals from natural medicinal plants such as anacardic acid (AA), garcinol, and curcumin have been shown to be potent inhibitors of p300 and PCAF (2–4). Among them, curcumin and garcinol are able to induce histone hypoacetylation in cancer cells, leading to apoptosis (2, 4, 36). In addition, garcinol and AA have served as excellent backbones from which a series of analogues have been synthesized and tested for activities inhibitory to HATs. Specifically, most of the 28 synthesized AA analogues could inhibit HAT activity in vitro and were cytotoxic to a wide range of cancer cells (23),
whereas one of the compounds was a p300 activator (3). Remarkably, modifications of garcinol have led to the identification of a p300-specific inhibitor which is relatively nontoxic to human cells but able to repress human immunodeficiency virus replication (42). The fact that most eukaryotes contain multiple HAT family members and their use of distinct catalytic mechanisms offer a good opportunity for designing specific inhibitors.

Drug-resistant malaria parasites are an escalating problem for malaria control, and there is an urgent need for novel chemotherapy. The completion of the Plasmodium falciparum genome sequence has provided insights into the biological pathways of pathogenesis and offered a great opportunity for identifying effective drug targets (29). The ∼2.3-megabase genome of the P. falciparum genome, containing ∼5,640 genes, is distributed among 14 chromosomes. Like those of other eukaryotes, the malaria parasite genome is packed with histones into chromatin (12, 43) and encodes a battery of enzymes that catalyze the dynamic addition and removal of covalent modifications of histones during development (14, 24, 43). The malaria parasite has PIGCN5 and a MYST family HAT homologue (PIMYST) but lacks a p300/CBP homologue (24). Histone acetylation in the parasite has been shown to regulate the monoallelic expression of the var genes, which mediates the antigene switching and virulence of the parasite (21, 27, 55, 56). A recent study revealed that varied expression of genes involved in erythrocyte invasion in different parasite clones may be also under epigenetic control (13), suggesting that an epigenetic mechanism is a conserved theme for genome-wide transcription regulation in this parasite. Furthermore, the H3 acetylation mediated by PIGCN5 appears to play a key role in gene activation in the parasite (16, 24). Consequently, disturbance of histone acetylation has negative impacts on parasite development and malaria parasite HATs are viable targets for therapy. For instance, the polyphenolic compound curcumin inhibits malaria parasite growth both in vitro and in vivo (45, 47), and this antiparasitic effect is partially due to downregulation of PIGCN5 HAT activity (15).

To further explore HAT enzymes as potential targets for controlling malaria, we assessed the effect of AA, an inhibitor for both p300 and PCAF HAT families, on PIGCN5 using in vitro and in vivo assays. AA, also known as 6-pentadecanolsaliclyllic acid, is found in plants of the family Anacardiaceae. Cashew nut shell liquid is a rich natural source, containing approximately 70% AA. We show here that AA inhibits PIGCN5 HAT activity and P. falciparum growth in culture. Consistent with the role of PIGCN5 in regulating global gene expression, AA treatment inhibits PIGCN5 activity, resulting in histone hypoacetylation and downregulation of a panel of developmentally regulated genes in the parasite.

MATERIALS AND METHODS

Inhibition of recombinant PIGCN5 by AA. A 50 mM stock solution of AA (C15:0) (Axoara, San Diego, CA) was made in dimethyl sulfoxide (DMSO). Its effect on the HAT activity of the recombinant PIGCN5 HAT domain was studied using an established HAT filter assay (15). Briefly, 1 μg (6.25 μM) of recombinant PIH3 and 30 ng (60 nM) of the recombinant PIGCN5 HAT domain were incubated in a HAT buffer in the absence (DMSO control) or presence of AA (10 to 60 μM) at 30°C for 10 min. The reaction mixtures were further incubated with 0.1 μCi of [3H]acetyl-CoA (Amersham, Piscataway, NJ) for 10 min, which was determined to be in the linear range of the reaction (data not shown). The reaction mixtures were blotted onto P-81 filters (Whatman, Florham Park, NJ), washed with 50 mM NaHCO3-Na2CO3 buffer (pH 9.2), and dried, and the radioactive counts were determined with a Beckman Coulter liquid scintillation counter (LSC). To study the inhibition kinetics of AA, the filter assays were performed similarly using a constant amount of recombinant PIH3 (10 μM) and increasing concentrations (6.5 to 1,080 nM) of [3H]Ac-CoA in the absence or presence of 10 and 15 μM of AA. The results were plotted using Kaleidograph software, version 3.5 (Synergy Software, Reading, PA). To determine whether the inhibitory effect of AA on PIGCN5 is reversible, HAT reaction mixtures were assembled with DMSO control or 10, 20, or 40 μM of AA. Whereas half of the reaction mixture was used directly for the HAT assay, the other half was dialyzed extensively for 30 min in a cold HAT buffer using a microdialyzer (Cole-Parmer, Vernon Hills, IL). Afterwards, the reaction was continued as described above, and radioactivity was measured by LSC. The assay was performed in triplicate, and the HAT activity was expressed as a percentage of the DMSO control, which was set as 100%. The relative HAT activities for the DMSO control and different concentrations of AA were compared using Tukey’s test.

Parasite culture and drug assays. In vitro drug assays were performed using chloroquine (CO)-sensitive P. falciparum strains 3D7 and D10 and CO-resistant strains Dd2 and 7G8. Parasites were cultured in human O+ erythrocytes at 5% hematocrit in RPMI 1640 supplemented with 25 mM HEPEs, pH 7.5, 2.5 mM sodium bicarbonate, 50 μl/g liter hypoxanthine, 0.5% Albumax II, and 40 μg/ml gentamicin sulfate. Cultures were maintained at 37°C in a gas mixture of 5% CO2 and 3% O2. Synchronization was carried out by two 5% sorbitol treatments of ring stage parasites (37). The inhibitory effect of AA on parasite growth was determined using a standard [3H]hypoxanthine labeling method with serial dilutions of AA at final concentrations of 5 to 100 μM (15, 20). Inhibition constant (IC) values were calculated by linear regression and analyzed using Kaleidograph. Statistical analysis of IC values between different parasite strains was performed using Tukey’s test. The long-term effect of a sub-50% IC (IC50) of AA (5 or 20 μM) on the growth of 3D7 and 7G8 strains was evaluated by daily examination of parasite morphology and parasitemias for 5 days at starting parasitemias of 0.5% and 5% hematocrit. To test whether AA treatment affected particular stages of the asexual parasites, synchronized 12-h ring stage parasites treated with 5 or 20 μM AA were monitored for development. The proportion of each stage was determined from 300 live parasites at 24, 36, 48, and 60 h.

AA inhibition of HAT and HDAC activity in parasites. To determine the effect of AA on PIGCN5 in cultured parasites, nuclear extracts were prepared from parasites treated with 0, 30, or 50 μM of AA for 12 and 18 h (15). HAT filter assays were performed using 1 μg (6.25 μM) of PIH3, 5 μl of nuclear extract from each treatment, and 0.1 μCi of [3H]Ac-CoA as described above. HDAC activity in cultured parasites was measured using a Histone Deacetylase kit (Millipore, Billerica, MA). Briefly, biotin-conjugated H4 peptide was radiolabeled by using PCAF and [3H]Ac-CoA and purified by streptavidin-conjugated agarose beads. In a 200-μl reaction mixture, 1 μl of each nuclear extract prepared as described above was incubated with 40,000 cpm of [3H]-acetylated H4 peptide at 37°C. After the addition of 50 μl of quenching solution, 100 μl of supernatant was used for counting with the LSC. Additionally, to test the effect of AA on HDAC in vitro, 10 μl of control nuclear extract and 40,000 cpm of [3H]-acetylated H4 peptide were incubated with 10, 20, and 30 μM of AA for 24 h and HDAC activity was measured with the LSC. The HDAC inhibitor sodium butyrate (200 mM) was included as a positive control. The differences in HAT and HDAC activity between control and treated parasites were analyzed by analysis of variance (ANOVA).

Effects of AA on histone modifications. To measure the effect of AA on covalent modifications of histone lysines in P. falciparum, histones were extracted from control 3D7 parasites and those treated with 20 μM of AA for 12 h (43). Equal amounts of histones were separated by 18% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed in Western blots with a panel of antibodies specific for histone acetylation and methylation on different lysine residues (Millipore). The specificity of these antibodies has been previously described (14, 43). To determine whether AA treatments resulted in change of PIGCN5 expression, 100 μg of protein extracts from parasites treated with 0 and 20 μM of AA for 12 h was separated by 4 to 12% NuPAGE gel (Invitrogen, Carlsbad, CA) and the PIGCN5 protein levels were estimated by immunoblotting with anti-PIGCN5 antibodies (25).

Microarray analysis. To evaluate the effect of AA on parasite global gene expression, 3 × 107 18-h-old synchronized trophozoites were treated for 12 h with 0, 5, 10, or 20 μM of AA. Microarray analysis was performed using spotted arrays consisting of 7,462 70-mer oligonucleotides (9). RNA was isolated from control and treated parasites using TRIzol reagent and treated with RNease-free DNase I (Promega, Madison, WI) to remove contaminating genomic DNA.
RESULTS

AA inhibits recombinant PGCGN5. AA was found to be a noncompetitive inhibitor of the HATs p300 and PCAF (3). To determine whether AA inhibits PGCGN5, a GNAT family HAT related to PCAF, we performed filter HAT assays using the recombinant PGCGN5 HAT domain (24). Compared with the solvent DMSO control, AA inhibited the HAT activity of the recombinant PGCGN5 with an IC50 of 26.6 μM (Fig. 1A). To determine whether inhibition of PGCGN5 by AA was reversible, dialysis was performed on preassembled HAT reaction mixtures. The results showed that inhibition of PGCGN5 HAT activity by AA was reversible and that the PGCGN5 HAT activity was fully restored after removal of AA by dialysis (Fig. 1B). To determine the nature of the inhibition, we analyzed the kinetics of PGCGN5 inhibition by AA. The double-reciprocal plot showed that, in the presence of AA, K_m changed little, whereas V_max of the reaction decreased (Fig. 1C). This indicated that AA acted as a noncompetitive inhibitor for PGCGN5, consistent with its mechanism of inhibition of other HAT members (3).

Effects of AA on global gene expression. To study the effect of AA on the cultured malaria parasite, we first tested the effect of a range of AA concentrations on synchronized ring stage P. falciparum 3D7 and found that 100 μM of AA completely blocked parasite growth. Using the [3H]hypoxanthine incorporation assay, we determined the IC50 for four parasite strains to be 30 to 34 μM and IC90 to be 54 to 57 μM (Table 1). No significant difference in sensitivity between the strains tested was found (Tukey’s t test, P > 0.05). Treatments with sub-IC50 concentrations of AA (5 and 20 μM) inhibited parasite growth to different degrees, and the growth curves for 3D7 and 7G8 strains were similar (Fig. 2A). After two asexual erythrocytic cycles, parasitemias in the controls had increased from 0.5 to almost 8%, whereas parasitemias in AA-treated parasites only reached less than 2.5%. At 20 μM of AA, parasite development and morphology appeared normal at 12 h, but growth retardation began to show at 24 h and became increasingly obvious at later time points, resulting in a less synchronous culture (Fig. 2B and C). We did not observe accumulation of a particular developmental stage, suggesting that AA’s action was not stage specific. In comparison, 50 μM of AA blocked parasite growth and gross morphological abnormalities such as chromatin condensation and vacuole formation were evident even at 24 h after treatment (Fig. 2B).

AA inhibits PGCGN5 in parasites. To establish whether AA could inhibit PGCGN5 activity in parasites, we treated parasites with 30 and 50 μM of AA (approximately IC50 and IC90) and evaluated HAT activity of the nuclear extracts using the filter assay. While 30 μM of AA did not result in significant changes in nuclear HAT activity for up to 24 h, 50 μM of AA led to only a 20% reduction in nuclear HAT activity (Fig. 3A). We further tested the effect of AA on parasite HDAC activity. Treatment of the 3D7 parasite with 30 and 50 μM of AA for 12 and 18 h had no visible effect on the HDAC activity of the nuclear extracts (Fig. 3B). When the HDAC assays were carried out with the addition of AA (10 to 50 μM) to a control nuclear extract, no changes in HDAC activity were observed compared to ~70% reduction of HDAC activity with sodium butyrate (Fig. 3C). To establish the effect of PGCGN5 on histone acetylation, we determined the acetylation status of parasite histones after AA treatment using antibodies specific for lysine acetylation and methylation of H3 and H4. The results showed that treatment of parasites with 20 μM of AA for 12 h did not lead to obvious changes in acetylation levels at four lysine residues of histone H4, nor did it affect H3K9 trimethylation (Fig. 4A). However, AA treatment significantly reduced acetylation of H3K9 and H3K14, suggesting that AA might have affected PGCGN5 activity. In addition, AA treatment did not cause apparent changes in the amount of PGCGN5 protein in the parasite, indicating that alteration of histone acetylation was likely due to inhibition of PGCGN5 (Fig. 4B).
FIG. 1. Effect of AA on recombinant PfGCN5 HAT activity. (A) Filter HAT assays with the recombinant PfGCN5 HAT domain and PfH3 in the absence or presence of different concentrations of AA. CPM, counts per minute. (B) Reversibility of AA's inhibition of recombinant PfGCN5. Filter HAT assays were assembled, and the reaction mixtures were either dialyzed or undialyzed before proceeding with the addition of [\(^{3}\text{H}\)]Ac-CoA. The HAT activity of reactions using AA was compared with that from DMSO controls, which was set as 100%. Results represent means and standard deviations from three replicates. (C) Lineweaver-Burk plot showing the inhibition kinetics of AA for PfGCN5, as measured with a constant amount of PfH3 and increasing amounts of [\(^{3}\text{H}\)]Ac-CoA.
TABLE 1. Sensitivity of four *P. falciparum* strains to AA in vitro*

<table>
<thead>
<tr>
<th>Parasite strain</th>
<th>IC_{50} (μM)</th>
<th>IC_{90} (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D7</td>
<td>30.41 ± 4.54</td>
<td>54.74 ± 5.31</td>
</tr>
<tr>
<td>D10</td>
<td>32.13 ± 1.41</td>
<td>57.83 ± 1.57</td>
</tr>
<tr>
<td>7G8</td>
<td>34.76 ± 0.57</td>
<td>60.75 ± 3.22</td>
</tr>
<tr>
<td>Dd2</td>
<td>31.06 ± 5.68</td>
<td>55.91 ± 6.73</td>
</tr>
</tbody>
</table>

*Values are means ± standard deviations from three replicates. Values in each column are not significantly different from each other at the *P* = 0.05 level (Tukey’s t test).*

ment and selected 20 μM of AA for 12 h, as this treatment did not cause observable changes in parasite growth but resulted in considerable alteration of global gene expression (data not shown). Using this established condition, we measured global gene expression in *P. falciparum* 3D7 with spotted arrays and compared levels of gene expression in control and AA-treated parasites. The results were highly reproducible, and there were high correlations among the three independent experiments (Pearson correlation, *R*^2^ > 0.8, *P* < 0.001). To enhance the consistency of the study and evaluate the effect of different degrees of PGCN5 inhibition, we tested three concentrations of AA for the microarray experiments. The results showed that treatment of 18-h late-ring stage parasites for 12 h with 5, 10, and 20 μM of AA led to a twofold or greater downregulation of 60, 109, and 207 genes and a twofold or greater upregulation of 66, 60, and 64 genes, respectively. Besides, among the genes downregulated at 5 and 10 μM of AA, 96.7% (58/60) and 86.9% (93/107) were also found in the downregulated gene pool at 20 μM of AA. These results also revealed that a greater number of genes were downregulated than upregulated, consistent with the effects of another HAT inhibitor, garcinol, and its derivatives on gene expression in HeLa cells (2, 42). The observed downregulation of a consistent set of genes agrees well with the expectation that reduced histone acetylation (possibly due to attenuation of PGCN5 activity) would lead to downregulation of gene expression. To further support this argument, we compared the results from this study with those from our earlier H3K9ac ChIP-chip analysis (16). Based on the notion that H3K9ac is associated with the promoter regions, we selected only genes whose microarray oligonucleotides are located within 500 bp of the putative ATG start codons. These included 82 genes downregulated twofold or greater by 20 μM of AA and 79 genes with fourfold or greater H3K9ac enrichment over the input genomic DNA. This analysis showed that >63% of genes identified in one study were also found in the other (Fig. 5A), indicating that genes highly enriched with H3K9ac at the putative promoter regions in our earlier mapping were correlated with genes downregulated by AA treatment (16). In contrast, upregulation by AA treatment was not dosage dependent, with similar numbers of parasite genes being upregulated by different AA concentrations. While this was not expected, a plausible explanation could be that the upregulation was not sensitive to dosage variation of AA at the concentration range used. Moreover, the pools of upregulated genes had only 21 (32 to 35%) genes in common, suggesting that AA increased expression of a large number of genes in a nonspecific manner.

Based on functional annotation of parasite genes in PlasmoDB, we classified the genes responsive to 20 μM AA treatment into potential functional categories. The largest category included 112 downregulated and 27 upregulated genes encoding hypothetical proteins with unknown functions. Genes encoding proteins with binding and catalytic/metabolic activity and genes involved in translation/transcription were among the most abundant groups shared between the down- and upregulated gene pools (Fig. 5B). The group of genes with binding activity that were downregulated by AA treatment included quite a few members of the multigene families var, rif, and clag, whose expression is under epigenetic control (13, 21, 27, 56). Whereas most of the responsive genes are...
distributed on different chromosomes, a cluster of four genes encoding the SERA (serine repeat antigen) cysteine proteases were downregulated (see Table S2 in the supplemental material). Eight SERA genes are clustered on chromosome 2, and they have similar expression profiles, with peak expression at late erythrocytic stages, suggesting that they might be coordinately regulated (44). In addition, a significant number of genes (~5%) encoding kinases and FIG. 3. Effects of AA on in vivo HAT and HDAC activity in *P. falciparum*. (A) HAT activity in equal amounts of nuclear extracts from control and AA-treated parasites for 12 and 18 h was measured using PfH3. The asterisks indicate that HAT activity in the nuclear extract of 50 μM-AA-treated parasites at 18 h was significantly different from that of the control (*P* < 0.01, ANOVA). (B) HDAC activity of the same nuclear extracts shown in panel A. There were no significant differences between the controls and AA-treated parasites at the two time points (*P* > 0.05, ANOVA). (C) HDAC assays were performed with a control nuclear extract incubated with DMSO, different concentrations of AA, or sodium butyrate. The means plus standard deviations (error bars) from three replicates are shown. AA (10 to 50 μM) had no significant effect on HDAC activity in the nuclear extract (*P* > 0.05, ANOVA).

FIG. 4. Effect of AA treatment (20 μM) for 12 h on histone acetylation and expression of PfGCN5. (A) Western blots of histone with a panel of antibodies specific for acetylated (ac) lysines (K) in histones H3 (K9 and K14) and H4 (K5, K8, K12, and K16) and antibodies for trimethylated H3K9 (3meK9). The Coomassie blue-stained gel indicates approximately equal loading. Histones were extracted from control (right lanes) and AA-treated (left lanes) parasites. (B) Western blot with antibodies against PfGCN5 using equal amounts of protein extracts (100 μg per lane) from control (C) and AA-treated parasites (AA). M indicates molecular markers.
phosphatases that are potentially involved in signal transduction were repressed rather than activated by AA treatment. A comparison of the proportions of these groups of genes in the genome indicated that only genes involved in binding and signal transduction had high representation among the AA-downregulated genes, whereas genes whose products had catalytic/metabolic activity, genes encoding chaperones, and genes expressed in gametocytes were enriched among the AA-upregulated genes (Fig. 5C). Since microarray analysis showed that AA treatments did not affect the expression of the HAT and HDAC genes, the deregulation of gene expression in the parasites by AA may not be the direct result of altered expression of these chromatin regulators. It is noteworthy that AA treatment disturbed the expression of a number of chaperones, DNA repair enzymes, and peroxidoxin, which implies a general stress response in the parasite (Fig. 5B; see Table S2 in the supplemental material). Furthermore, such stress was reflected in the upregulation of two known early gametocyte genes (Pfg27/25 and Pfs16) and several gametocyte-specific genes, as gametocytogenesis is often indicative of a parasite’s response to stress (11).

FIG. 5. Microarray analysis to determine global expression response to 20 μM of AA treatment for 12 h. (A) Venn diagram showing the overlap of genes that were downregulated twofold or greater by AA treatment and those that had fourfold or greater enrichment with H3K9ac over input genomic DNA (16). Note that only genes whose microarray oligonucleotides are within 500 bp of the putative ATG codons were chosen for this analysis. (B) Numbers of different functional categories of genes with twofold or greater downregulation or upregulation by AA treatment. Note that genes encoding hypothetical proteins are not shown. (C) Proportion of genes within each functional category in AA-deregulated pools and the parasite genome.
We have performed cluster analysis on the expression profiles of the genes with twofold or greater changes after 20 μM AA treatment (see Fig. S1 in the supplemental material). The results showed that the majority of the downregulated genes were active at the time of the microarray analysis according to the 48-h expression profile (9). As for the upregulated genes, only a small portion (13/64) were expressed; the majority of them were silent at the time of microarray analysis. Taken together, these results indicated that AA mostly downregulated active genes, whereas most of the upregulated genes were silent in late trophozoites.

Validation of differentially expressed genes after AA treatment. The relative expression levels of genes displaying alteration in response to AA treatment were further evaluated by real-time RT-PCR analysis (Fig. 6). We selected 11 downregulated, three upregulated, and three invariant genes for RT-PCR analysis. We were particularly interested in the category of genes potentially involved in signaling pathways. Among the 11 AA-downregulated genes selected for validation, 10 encode putative protein kinases or phosphatases. The semiquantitative and real-time RT-PCR results confirmed that AA treatment repressed the expression of the 11 genes, and their expression levels appeared inversely correlated with AA concentrations (Fig. 6A and B). In contrast, the expression levels of three AA-upregulated genes (heat shock protein 70, DNA repair helicase, and peroxidoxin genes) that are potentially involved in detoxification were all elevated in AA-treated parasites. Consistently, AA treatment did not affect the expression of the three unchanged genes from microarray analysis.

We have shown that PIGCN5-mediated H3K9ac is associated with active genes at the promoter region and that the reduced gene expression after treatment with another HAT inhibitor, curcumin, is partially due to reduced H3 acetylation at the promoters of these genes (15). ChIP and real-time PCR analysis of the same set of selected genes detected a dramatic reduction of H3K9ac in the upstream regions of downregulated genes compared to insignificant changes in the 5′ regions of most upregulated and invariant genes (Fig. 7). Compared with the control, all downregulated genes had significant reduction in H3K9ac at the 5′ regions at the higher AA concentrations (10 and 20 μM), whereas one-half of the selected genes also experienced a significant level of hypoacetylation at 5 μM of AA (Fig. 7A). These results indicated that AA treatment resulted in H3K9 hypoacetylation (possibly through in-
DISCUSSION

To date, a number of synthetic and natural compounds have recently been identified as HAT inhibitors (54). Of the naturally occurring compounds, AA and garcinol are potent inhibitors of both p300 and PCAF, while curcumin is only active against p300 (2–4). Target specificity is important for developing effective chemotherapeutics. However, the specificity of these HAT inhibitors for the broad spectrum of HAT families has not been fully tested. For example, AA has recently been found to also inhibit the MYST family HAT member Tip60, thus blocking the acetylation and activation of the ATM protein kinase in HeLa cells and sensitizing the cells to the cytotoxic effects of radiation (51). In addition, we have previously documented that curcumin, which is not active against human PCAF, is able to inhibit PIGCN5, a GNAT family member (15). This could result from the significant divergence of PIGCN5 from its mammalian counterparts (24). In this study, we have shown that AA possesses equally potent antiparasitic activity against both CQ-sensitive and -resistant parasite strains. Despite limited cell permeability in mammalian cells, AA still effectively blocked the development of intraerythrocytic parasites, suggesting that AA is accessible to the parasites. This enhanced accessibility possibly owes to the increased permeability of the red cell membrane due to extensive remodeling by the parasite (33). While our in vitro and in vivo data strongly suggest that the parasite-toxic effect of AA is due to its inhibition of PIGCN5 activity, we observed only insignificant reduction of HAT activity in nuclear extracts at concentrations of AA inhibitory for parasite growth. While the reason for this discrepancy is not clear, it is possible that the reversible binding of AA to PIGCN5 may have resulted in the partial loss of AA and restoration of PIGCN5 activity during the preparation of nuclear extracts. This argument is supported by the observation of H3K9 and H3K14 hypoacetylation at 20 μM of AA inhibition of PIGCN5 activity (15). This could result from the significant divergence of PIGCN5 from its mammalian counterparts (24).
despite that fact that this concentration did not induce loss of PfGCN5 HAT activity in nuclear extracts. We have shown that H3K9 and H3K14 are the preferred sites for PfGCN5, whereas PfMYST preferentially acetylates H4K8 and H4K12 (15; J. Miao et al., unpublished data). The effect of AA and curcumin on PfGCN5 may also affect nonhistone targets in malaria parasites which remain to be identified. Moreover, the biological activity of AA may be in addition to its actions against other unidentified targets in the malaria parasites, since AA is known to inhibit a large spectrum of enzymes in other organisms (reference 32 and references therein). Therefore, at present, the parasiticidal effect of AA could be only partially attributed to its inhibition of PfGCN5.

Genome-wide expression profiling has been successfully used to identify the pathways that particular drugs act on and to elucidate the possible resistance mechanisms. In yeasts, this has led to the identification of a coordinated transcriptional response to specific antifungal drug categories as well as genes that belong to the general detoxification responses (see, e.g., references 1, 5, and 40). In some cases, the response to chemical perturbation is profound: chemical carcinogens could evoke significant changes in transcript level for more than one-third of the ~6,200 genes in budding yeast (34). This is in sharp contrast to what is found for the malaria parasite, where attempts to relate global gene expression changes to perturbation with antimalarial drugs often detect either subtle changes in steady-state RNA levels or non-function-related changes as the result of altered growth rates of the treated parasites (18, 30, 31), which led to the speculation that the malaria parasite transcription regulatory network is probably “hardwired.” However, some studies did find consistent impact of drug treatments on specific metabolic pathways of the parasite, suggesting that the parasite has some capacity to respond at the transcript level to environmental perturbations (17, 18). In this study, we found that AA treatment at a sub-IC50 for a short period of time resulted in twofold or greater changes in ~5% of the parasite genes in late trophozoites. Our finding also concurs with findings for other organisms such as baker’s yeast, where the extent of transcriptional response was correlated with the concentrations of the chemicals (6, 34). Besides, most of the AA-responsive genes were downregulated, possibly due to induced hypoacetylation of H3K9 at the promoters of active genes. Interestingly, both CQ and AA affected a category of the AA-responsive genes were downregulated, possibly due to induced hypoacetylation of H3K9 at the promoters of active genes linked to erythocyte invasion. PLoS Pathog. 3:e1032–1033.


We thank the NIH for grant support (AI064553) to L.C. and the Division of Intramural Research, NIAID, NIH, for support to X.S.

REFERENCES


2. Balasubramanyam, K., M. Altf, R. A. Varier, V. Swaminathan, A. Ravind-


4. Balasubramanyam, K., R. A. Varier, M. Altf, V. Swaminathan, N. B. Sidd-


13. Cortes, A., C. Carret, O. Kaneko, B. Y. S. Y. Lim, A. Ivens, and A. A. Holder. 2007. Epigenetic silencing of Plasmodium falciparum genes linked to eryth-


